NYSE:ABTMedical Equipment
Will New Diabetes and Cardio Data Shift Abbott Laboratories' (ABT) Chronic-Disease Innovation Narrative
Earlier this month, Abbott Laboratories reported that its FreeDM2 randomized controlled trial found the FreeStyle Libre continuous glucose monitoring system improved HbA1c, time-in-range, and quality-of-life outcomes for people with Type 2 diabetes on basal insulin, while also launching its latest XIENCE Skypoint coronary stent in India to support treatment of complex heart blockages.
Together, these advances in diabetes care and cardiovascular devices highlight Abbott’s push to deepen its...